Business
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM
About this update from Relmada Therapeutics, Inc.
[{"type":"image","alt":"Relmada Therapeutics","displaySize":"","headline":null,"caption":"Relmada Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":130,"height":33,"url":"https://media.zenfs.com/en/globenewswire.com/864e8ce076842deb8ff51dcb2351bb2e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ttP74diEks8HOrImNeTk.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/864e8ce076842deb8ff51dcb2351bb2e","width":130,"height":33}},"lazy":false},{"type":"text","content":"CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress.","length":421,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast Information:","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Date: Monday, May 12, 2025 at 4:30 PM ET","length":40,"tagName":"p"}]},{"val":[{"type":"text","content":"Participant Dial-in (US): 1-877-407-0792","length":40,"tagName":"p"}]},{"val":[{"type":"text","content":"Participant Dial-in (International): 1-201-689-8263","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"Conference: 13753596","length":20,"tagName":"p"}]},{"val":[{"type":"text","content":"Webcast Access: Click Here","length":26,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":177,"olType":false},{"type":"text","content":"A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.","length":144,"tagName":"p"},{"type":"text","content":"About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.","length":248,"tagName":"p"},{"type":"text","content":"Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to adva...